UNSPSC 51432204: Dihydralazine mesilate

This classification denotes an antihypertensive agent with the molecular formula C8H10N6.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V8BVP5X5E. European Medicines Agency schedules dihydralazine mesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB20331. Most nations, for tariff and trade purposes, schedule dihydralazine mesilate under HS 29339990 and SITC 51577. SMILES: CS(=O)(=O)O.C1CCC2C(C1)C(NNC2NN)NN.

UNSPSC 51432204 Dihydralazine mesilate is a Commodity code covering a single pharmaceutical product used in emergency medical settings. State and local governments procure this medication primarily through fire departments, EMS agencies, and pharmacy benefit programs that support hospital systems and public health networks. The scope of work encompasses supply of the pharmaceutical itself, management of inventory expiration and replacement logistics, and compliance with manufacturing standards, FDA approval, and safety documentation requirements. Issuing bodies include municipal fire departments, state health and human services agencies, and cooperative purchasing alliances that aggregate demand across multiple state and local members. The City of Tampa and the Texas Health and Human Services Commission represent the types of jurisdictions and agencies actively soliciting pharmaceutical products under this and closely related codes.

Recent activity centers on Florida and Texas, with broader multistate participation through cooperative purchasing vehicles. The City of Tampa's Fire Rescue issued IFB 26P00188 in April 2026 for Advanced Life Support Medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem—medications in the same therapeutic and delivery categories as dihydralazine mesilate—with a response date of April 8, 2026 and an estimated contract value of $40,000. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local facilities, with responses due March 26, 2026 and contract effectiveness July 1, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for direct-to-manufacturer prescription programs. Vendors must comply with cGMP, FDA requirements, DSCSA, and OSHA Hazard Communication Standards; maintain minimum shelf life and expiration-date warranties; and coordinate with authorized wholesalers and state pharmacy benefit managers for distribution.